eltoprazine has been researched along with Parkinson Disease in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bezard, E; Carta, M; Cheng, LY; Ko, WKD; Li, Q; Morelli, M | 1 |
| Bezard, E; Carta, M | 1 |
| Af Edholm Arvidsson, K; Björklund, A; Keywood, C; Lowe, DA; Rosenblad, C; Shankar, B; Svenningsson, P; Wictorin, K; Widner, H | 1 |
| Arcuri, L; Brugnoli, A; Mercatelli, D; Morari, M; Paolone, G | 1 |
| Carta, M; Cenci, MA | 1 |
| Bezard, E; Carta, M; Costa, G; Fidalgo, C; Ko, WK; Li, Q; Morelli, M; Pinna, A; Simola, N; Tabrizi, MA; Tronci, E | 1 |
| Bezard, E; Björklund, A; Carta, M; Li, Q; Pioli, EY; Porras, G; Tronci, E | 1 |
1 trial(s) available for eltoprazine and Parkinson Disease
| Article | Year |
|---|---|
Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.
Topics: Aged; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Piperazines | 2015 |
6 other study(ies) available for eltoprazine and Parkinson Disease
| Article | Year |
|---|---|
A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L-DOPA-induced dyskinesia in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Motor Activity; Parkinson Disease; Piperazines; Time Factors | 2017 |
Could the serotonin theory give rise to a treatment for levodopa-induced dyskinesia in Parkinson's disease?
Topics: Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Parkinson Disease; Piperazines | 2015 |
Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Functional Laterality; gamma-Aminobutyric Acid; Gene Expression Regulation; Glutamic Acid; Levodopa; Male; MAP Kinase Signaling System; Motor Activity; Oxidopamine; Parkinson Disease; Piperazines; Rats; Rats, Sprague-Dawley; Serotonin Receptor Agonists; Time Factors | 2015 |
On the Effect of Eltoprazine in Dyskinetic Hemiparkinsonian Rats.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Parkinson Disease; Piperazines; Rats; Serotonin Receptor Agonists | 2016 |
Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Male; Parkinson Disease; Piperazines; Pyrimidines; Rats; Rats, Sprague-Dawley; Serotonin Receptor Agonists; Triazoles | 2016 |
Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.
Topics: Amantadine; Amphetamine; Animals; Apomorphine; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Medial Forebrain Bundle; Motor Activity; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Piperazines; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Serotonin Receptor Agonists; Time Factors; Tyrosine 3-Monooxygenase | 2013 |